相关实验视频

Updated: Jan 12, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

第一线免疫疗法与二线TKI结局在转移性细胞癌中的相关性

Koichi Sugimoto¹, Takafumi Minami¹, Takuhisa Nukaya²

¹Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Cancer diagnosis & prognosis

|November 3, 2025

概括

对于转移性细胞癌 (mRCC) 患者,一线免疫检查点抑制剂 (ICI) 后的无进展生存期 (PFS) 与二线氨酸激酶抑制剂 (TKI) PFS没有相关性,除了低风险患者.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞癌研究细胞癌研究

背景情况:

免疫检查点抑制剂 (ICI),如尼沃卢马布 (NIVO) 加上伊皮利穆马布 (IPI),改善了转移性细胞癌 (mRCC) 的存活率.
一线ICI后的进展很常见,需要有效的二线疗法,通常是氨酸激酶抑制剂 (TKI).
在mRCC治疗ICI后,在一线和二线设置中无进展生存 (PFS) 之间的关系尚不清楚.

研究的目的:

研究转移性细胞癌 (mRCC) 患者的一线和二线无进展生存 (PFS) 之间的相关性.
分析mRCC患者的治疗结果,这些患者接受了免疫检查点抑制剂 (ICI),其次是氨酸激酶抑制剂 (TKI).

主要方法:

对66名接受一线NIVO + IPI,随后接受TKIs的mRCC患者的回顾性分析.
数据从2018年9月到2023年2月在多个中心收集.
用国际转移性RCC数据库联盟 (IMDC) 的风险分类来分层患者.

主要成果:

第二线TKIs的PFS中位数为6.9个月;整体存活时间为17.7个月.
在整体队列或中等风险子组中,没有发现一线和二线PFS之间的显著相关性.
在低风险组中观察到一线和二线PFS之间的显著正相关性 (斯皮尔曼的rho=0.677,p=0.002).

结论:

低风险mRCC患者的治疗结果可能会在不同治疗线路中显示出可预测的反应模式.
这些发现表明,基于mRCC.风险分层的个性化治疗策略的潜力.

关键词:

相关性分析的相关性分析.这里是 ipilimumab 的所在地.mRCCCC 是一个很好的选择.这就是尼沃卢马布 (nivolumab).铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...